Save the Dates!

ASPN Summer Webinar Series #1 - July 10, 2020 - 2-4pm Eastern
Urine in the Know - Advocacy: Past, Present and Future Perspectives

Brief Description of Overall Session:   The “Urine the Know” workshop has become a popular staple of the ASPN Program to promote recent research highlights from early career investigators and feature lectures from established faculty. This year’s session will dedicate the first hour to celebrate cutting-edge research published over the past year by junior faculty and trainees. In the second hour, we will focus on ASPN advocacy, celebrating 10 years of JELF scholars. This will focus on the history, current status, and future directions of advocacy in pediatric renal disease. Following the lectures, we will end with a Q&A of current and past JELF scholars.

1. Highlight recently published, cutting-edge research from junior faculty and trainees.
2. Review the history ASPN advocacy.
3. Explore the current issues in advocating for pediatric nephrology patients.
4. Discuss the future directions of advocacy in pediatric renal disease.

Moderators:

Kimberly Reidy, MD
Children's Hospital at Montefiore
Albert Einstein College of Medicine

Michelle Starr, MD
Riley Hospital for Children
Indiana University

Speakers:

1. Best articles of 2019
   1. Modi ZJ et al. Risk of Cardiovascular Disease and Mortality in Young Adults with End-Stage Renal Disease: An Analysis of theUS Renal Data System. JAMA Cardiology
      Zubin Modi, MD
      University of Michigan Health Systems
   2. Mann, N. et al. Whole-Exome Sequencing Enables a Precision Medicine Approach for Kidney Transplant Recipients. JASN.
      Nina Mann, MD
      Children's Hospital Boston - Harvard Medical School
   3. Kizilbash SJ, et al. Kidney transplant outcomes associated with the use of increased risk donors in children. American Journal of Transplantation
      Sarah Kizilbash, MD
      Department of Pediatrics, Division of Nephrology
      University of Minnesota
   4. Menon S, et al. Kidney Support in Children using an Ultrafiltration Device: A Multicenter, Retrospective Study. CJASN.
      Shina Menon, MD
      Pediatric Nephrology
      Seattle Children's Hospital
2. A historical perspective of ASPN advocacy and development of the JELF scholarship program
   David Hains, MD
   Riley Hospital for Children
3. Clear and present danger: what are the advocacy issues that pediatric nephrologist face today?
   Veronique Phan, MD, MSc
   CHU Ste-Justine
4. Shaping the future: opportunities for advocacy in pediatric nephrology
   Kiri Bagley
   University of NC at Chapel Hill
5. Q&A of current and past JELF scholars 

1. 1. Patty Seo-Mayer, MD, FAAP, FASN
      Pediatric Specialists of Virginia and Inova Children’s Hospital
   2. Kimberly Reidy, MD
      Children's Hospital at Montefiore
      Albert Einstein College of Medicine
   3. David Hains, MD
      Riley Hospital for Children
   4. Kiri Bagley, MD
      University of North Carolina
   5. Michelle Starr, MD
      Riley Hospital for Children
      Indiana University

ASPN Summer Webinar Series #2 - July 17, 2020 - 2-4pm Eastern
Using TOD²AY to improve tomorrow’s renal outcomes in childhood diabetes

Brief Description of Overall Session:  This symposium will highlight cutting edge research in pediatric diabetic nephropathy.  Diabetes is the leading cause of end stage renal disease in adults, but the kidney complications of pediatric patients with diabetes have been understudied.  In this session, the long-term kidney complications of both type 1 and 2 diabetes will be reviewed.  Next, speakers will highlight discoveries from the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study.  The TODAY study is the first multicenter randomized trial in the United States to compare treatment approaches in 699 children, ages 10-17 years, with new-onset type 2 diabetes. This seminal cohort has allowed for the development of biomarkers to predict renal progression and therapies for pediatric diabetic nephropathy, and provided insight into the optimal care of children with type 2 diabetes.  This session will conclude by highlighting the risk factors, therapeutic options and long-term prognosis for patients who develop diabetes follow kidney transplantation.

Objectives:

1. Review the long-term kidney complications of both type 1 and 2 diabetes.
2. Highlight discoveries from the TODAY study.
3. Explore novel therapies for pediatric diabetic nephropathy.
4. Review risk factors and therapeutic options for the development of diabetes after kidney transplant.

Moderators:

Daniella Levy-Erez, MD
Children's Hospital of Philadelphia

Elaine Ku, MD
University of California, San Francisco

Speakers:

1. Longitudinal kidney and cardiovascular outcomes in type 1 and type 2 diabetes
   Mark Mitsnefes, MD
   Cincinnati Children's Hospital
2. Lessons from the TODAY Study: Biomarkers to predict the progression of renal disease in type 2 diabetes
   Petter Bjornstad, MD
   Children's Hospital Colorado Anschutz Medical Campus
3. Therapy algorithms and new therapies for pediatric diabetic nephropathy
   Edward Nehus, MD, MS
   Cincinnati Children’s Hospital Medical Center
4. Diabetes after kidney transplant
   Mary Ellen Vajravelu, MD
   Children's Hospital of Philadelphia